Prothena Corporation plc

PRTA

NASDAQ. Currency in USD

58.36 -0.81 ( -1.37% )

Real time prices: December 09

Market Cap.
2.82B
Beta (5Y monthly)
0.50
Price/Earnings
-
EPS (TTM)
-3.34
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
311,819
1y Target Est.
82.67
Day's Range
58.33
-
59.99
52 Week's Range
21.06
-
66.47

Historical Summary

Performance
EPS growth
Share Buybacks

About Prothena Corporation plc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.prothena.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
46.59M
Employees
82
Address
77 Sir John Rogerson?s Quay, Dublin, Ireland, 2
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Latest news

Biogen (BIIB) Down on Report of Death in Alzheimer's Study
Biogen (BIIB) Down on Report of Death in Alzheimer's Study

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who...
By Zacks Investment Research - 1 week ago

Prothena (PRTA) Earns Milestone Payment From Novo Nordisk
Prothena (PRTA) Earns Milestone Payment From Novo Nordisk

Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of...
By Zacks Investment Research - 2 weeks ago

One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments
One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments

Biogen stock is rising as investors double down on the company’s promising yet still experimental...
By MarketWatch - 3 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Upgrades Citigroup upgraded the previous rating for Advanced Energy Industries Inc (NASDAQ:AEIS) from Neutral to...
By Benzinga - 5 weeks ago

What 4 Analyst Ratings Have To Say About Prothena Corp
What 4 Analyst Ratings Have To Say About Prothena Corp

Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings: Bullish Somewhat...
By Benzinga - 5 weeks ago

As Small Caps Rally, These 3 Finance High-Yielders Could Have Further Upside
As Small Caps Rally, These 3 Finance High-Yielders Could Have Further Upside

In the past month with the Russell 2000 index up roughly 7%, as compared to...
By Benzinga - 6 weeks ago

Prothena to Report Third Quarter 2022 Financial Results on November 3rd
Prothena to Report Third Quarter 2022 Financial Results on November 3rd

DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical...
By GlobeNewswire Inc. - 6 weeks ago

Annovis (ANVS) Gains on FDA Authorization for AD Study
Annovis (ANVS) Gains on FDA Authorization for AD Study

Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical...
By Zacks Investment Research - 9 weeks ago